Trial Profile

A Clinical Study to Evaluate MT-201 (ATAK primed monocytes) in Glioblastoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MT-201-Myeloid-Therapeutics (Primary)
Indications Glioblastoma
Focus Adverse reactions
Sponsors Myeloid Therapeutics

Most Recent Events

14 Jan 2021 New trial record
06 Jan 2021 According to a Myeloid Therapeutics media release, Myeloid Therapeutics has been launched today with over $50 million in financing to initiate multiple clinical trials in 2021.The company expects to enter the clinic with ATAK primed monocytes in glioblastoma in 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com